MUMBAI, India, Sept. 22 -- Intellectual Property India has published a patent application (202617070592 A) filed by Sanofi on June 05, 2026, for Cd25 Based Lysosomal Degrader And Uses Thereof.
Inventors include Li, Xiangming; Mukai, Kaori; Park, Sunghae; Sun, Victor Zhao; Zhou, Qun; and Heyninck, Karen.
The application for the patent was published on September 18, 2026, under issue no. 38/2026.
Abstract: The present disclosure provides a method comprising: contacting a CD25 positive cell with either a multispecific or a monospecific CD25 binding protein. The multispecific binding protein can comprise: a) a first cell surface binding moiety that specifically binds to CD25 on the surface of the CD25 positive cell, wherein the first cell surface binding moiety comprises at least one immunoglobulin domain or an antigen binding fragment thereof; and b) a second binding moiety that is operatively linked to the first cell surface binding moiety and that specifically binds to the target protein, wherein specific binding of the multispecific binding protein to the CD25 facilitates the internalization of the target protein into the CD25 positive cell. The internalization results in lysosomal degradation of the target protein. A monospecific CD25 binding protein can comprise at least one ISVD that specifically binds to a CD25 (CD25 ISVD) on the surface of a CD25 positive cell and can be utilized in a multispecific CD25 binding protein. The binding of the monospecific CD25 binding protein can modulate cell regulation, e.g., resulting in inactivation of T cells. The present disclosure also provides multispecific and monospecific binding protein compositions, host cells for making the multispecific and monospecific binding protein compositions, and methods of using the multispecific and monospecific binding protein compositions to treat disease.
Disclaimer: Curated by HT Syndication.
